On behalf of the programme chairs, we are delighted to invite you to the Gilead Haematology Medical Education Programme in lymphoid malignancies focusing on Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL). This will consist of a series of regional meetings held around the UK.
Register your interest now to secure your place at a meeting near you.
These meetings will be held by regional experts and will include:
- Interactive real-world case studies typically encountered by clinicians
- Discussion on the role of cytogenetics and advanced diagnostic techniques in patient management
- A practical guide to the multi-disciplinary management of side-effects within the changing treatment landscape
We look forward to welcoming you to these meetings.
10:00 am – 4:00pm
17:30 – 20:30
18:00 – 20:30
12:00 – 18:00
To register your attendance at any of the upcoming events, visit the Events Registration page.
Find out more about the meetings series on the Meetings page.
Continuing Professional Development (CPD) accreditation for these meetings has been applied to the Royal College of Physicians (RCP) and more information will be available shortly. Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing.
This is a medical education meeting organised and funded by Gilead Sciences Ltd., a science-based pharmaceutical company. This meeting is a medical education programme designed for healthcare professionals based in the UK and the Republic of Ireland only.
Date of preparation MONTH YEAR
Date of preparation: August 2018
This activity is intended for medical Haematology/Oncology specialists, Pathologists, Pharmacists, Nurses and other healthcare professionals involved in the management of CLL/FL. This is a medical education meeting organised and funded by Gilead Sciences Ltd., a science-based pharmaceutical company. This meeting is a medical education programme designed for healthcare professionals based in the UK and the Republic of Ireland only.